Cointime

UNITY Biotechnology

company

About

Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging.

  • 51 - 100

Highlights

Total Funding Amount
$288.30M
Funding Rounds
5
Investors
3

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$80M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2009
Number Of Employee
51 - 100
Operating Status
Active

Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$288.30M
UNITY Biotechnology has raised a total of $288.30M in funding over 2 rounds. Their latest funding was raised on Aug 4, 2020 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 4, 2020 Post-IPO Debt $80M 1 Hercules Capital — Detail
Mar 19, 2018 Series C $55M 2 — — Detail
Aug 17, 2017 Series B $35M 2 ARCH Venture Partners — Detail
Oct 27, 2016 Series B $116M 1 — — Detail
Jan 1, 2015 Series A $2.30M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
2
3
UNITY Biotechnology is funded by 3 investors. Hercules Capital and ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
ARCH Venture Partners — Series C
Pivotal Alpha Limited — Series C
Cointime
Chủ Đề
Công Ty